Elasmogen Ltd is another successful and award winning spin-out from the University of Aberdeen’s, Scottish Biologics Facility and part of the growing biologics cluster of companies found in the Aberdeen city area.
Elasmogen Ltd is discovering and developing soloMER™s for the treatment of auto-immune mediated, inflammatory diseases. Utilising its unique soloMER™ platform, Elasmogen exploits the power of biologics as drugs but in small, simple, and stable formats that are amenable to site-specific delivery.
Elasmogen is progressing sight-saving therapies for inflammatory eye disease and in particular for those patients that have been let down by current small molecule and systemic monoclonal antibody therapies. With collaborators Elasmogen is also developing targeted and potent therapies for the treatment of solid tumours.